<PAGE>
===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period ended June 30, 1998
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________________ to __________________
Commission File No. 0-19651
___________________________
Magainin Pharmaceuticals Inc.
_____________________________
(Exact name of registrant as specified in its charter)
Delaware 13-3445668
________ __________
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification Number)
5110 Campus Drive
Plymouth Meeting, Pennsylvania 19462
______________________________ _____
(Address of principal executive offices) (ZIP Code)
610-941-4020
____________
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports to be
filed by Section 13 of 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the Registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes X No
______ _______
The number of outstanding shares of the Registrant's Common Stock, par value
$.002 per share, on August 10, 1998 was 22,289,863.
================================================================================
<PAGE>
MAGAININ PHARMACEUTICALS INC.
INDEX
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Page
------
Part I - Financial Information
<S> <C>
Item 1. Financial Statements
(unaudited)
Balance Sheets
as of June 30, 1998 and December 31, 1997 3
Statements of Operations
for the three and six months ended June 30, 1998 and June 30, 1997 4
Statements of Cash Flows
for the six months ended June 30, 1998 and June 30, 1997 5
Notes to Financial Statements 6
Item 2. Management's Discussion and Analysis
of Results of Operations and Financial Condition 10
Part II - Other Information 15
</TABLE>
2
<PAGE>
MAGAININ PHARMACEUTICALS INC.
BALANCE SHEETS
(In thousands -- except per share amounts)
<TABLE>
<CAPTION>
June 30, 1998 December 31, 1997
------------- -----------------
(Unaudited)
<S> <C> <C>
Assets
Current assets:
Cash and cash equivalents $ 1,142 $ 487
Short-term investments 27,704 38,574
Prepaid expenses and other current assets 419 490
--------- ----------
Total current assets 29,265 39,551
Fixed assets, net 3,139 2,824
Other assets 99 69
--------- ----------
Total assets $ 32,503 $ 42,444
========= ==========
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $ 6,966 $ 5,944
Current portion of note payable - 500
Current portion of capital lease obligations - 34
--------- ----------
Total current liabilities 6,966 6,478
Note payable 2,500 1,000
Deferred rent 77 96
--------- ----------
Total liabilities 9,543 7,574
--------- ----------
Commitments, contingencies and other matters
Stockholders' equity:
Preferred stock -- $.001 par value; 9,211 shares authorized,
none issued - -
Common stock -- $.002 par value; 45,000 shares authorized,
22,278 and 21,980 shares issued and outstanding 45 44
Additional paid-in capital 145,430 144,444
Accumulated other comprehensive income 32 6
Accumulated deficit (122,547) (109,624)
--------- ----------
Total stockholders' equity 22,960 34,870
--------- ----------
Total liabilities and stockholders' equity $ 32,503 $ 42,444
========= ==========
</TABLE>
See Notes to Financial Statements.
3
<PAGE>
MAGAININ PHARMACEUTICALS INC.
STATEMENTS OF OPERATIONS
(unaudited)
(In thousands -- except per share amounts)
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
June 30, June 30,
------------------------- -------------------------
1998 1997 1998 1997
---- ---- ---- ----
<S> <C> <C> <C> <C>
Revenues:
Contract revenues $ -- $ 5,038 $ -- $ 10,075
Costs and expenses:
Research and development 5,684 5,830 11,905 10,537
General and administrative 968 784 1,878 1,649
-------- -------- -------- --------
6,652 6,614 13,783 12,186
-------- -------- -------- --------
Loss from operations (6,652) (1,576) (13,783) (2,111)
Interest income 429 428 944 870
Interest expense (50) (22) (84) (44)
-------- -------- --------- --------
379 406 860 826
-------- -------- --------- --------
Loss $(6,273) $(1,170) $(12,923) $(1,285)
======== ======== ========= ========
Loss per share - basic $ (.28) $ (.06) $ (.58) $ (.07)
======== ======== ========= ========
Weighted average shares outstanding
22,256 19,365 22,174 19,364
======== ======== ========= ========
</TABLE>
See Notes to Financial Statements.
4
<PAGE>
MAGAININ PHARMACEUTICALS INC.
STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
<TABLE>
<CAPTION>
Six Months Ended
June 30,
----------------------------
1998 1997
---- ----
<S> <C> <C>
Cash Flows From Operating Activities:
Loss $ (12,923) $ (1,285)
Adjustments to reconcile loss to
net cash used in operating activities:
Depreciation and amortization 598 454
Issuance of common stock under manufacturing agreement 859 --
Deferred rent (19) (16)
Changes in operating assets:
(Increase) decrease in prepaid expenses and
other assets (324) (109)
Increase (decrease) in accounts payable and
accrued expenses 1,022 (265)
---------- ---------
Net cash used in operating activities (10,787) (1,221)
---------- ---------
Cash Flows From Investing Activities:
Purchases of investments (22,644) (31,657)
Proceeds from maturities and sales of investments 33,900 32,465
Purchase of fixed assets (913) (917)
---------- ---------
Net cash provided by (used in) investing activities 10,343 (109)
---------- ---------
Cash Flows From Financing Activities:
Proceeds from borrowings under note payable 1,000 -
Payments on capital lease obligations (28) (66)
Proceeds from exercise of employee stock options and warrants 127 9
---------- ---------
Net cash provided by (used in) financing activities 1,099 (57)
---------- ---------
Net increase (decrease) in cash and cash equivalents 655 (1,387)
Cash and cash equivalents, beginning of period 487 2,072
---------- ---------
Cash and cash equivalents, end of period $ 1,142 $ 685
========== ==========
Supplemental disclosure of cash flow information:
Cash paid for interest during the period $ 80 $ 44
========== ==========
</TABLE>
See Notes to Financial Statements.
5
<PAGE>
MAGAININ PHARMACEUTICALS INC.
Notes To Financial Statements
(unaudited)
1. Company Background
Magainin Pharmaceuticals Inc. (the "Company") was incorporated on June 29,
1987. The Company is a biopharmaceutical company engaged in the development of
medicines for serious diseases. The Company's development efforts are focused on
anti-infectives, oncology, and pulmonary and allergic disorders.
The Company has submitted a New Drug Application (NDA) with the United
States Food and Drug Administration ("FDA") for its lead product development
candidate, pexiganan acetate (formerly called "Cytolex"), a topical cream
antibiotic intended for the treatment of infection in diabetic foot ulcers. The
Company is also conducting research on an aminosterol class of compounds. One
such compound, squalamine, is currently being evaluated in Phase I clinical
testing in cancer. The Company conducts additional research efforts in the
genomics of asthma.
The Company has not generated any revenues from product sales, and has
funded operations primarily from the proceeds of public and private placements
of securities. Substantial financing will be required by the Company to fund its
continuing research and development activities. There can be no assurance that
such financing will be available when needed or that the Company's research and
development efforts will be successful.
2. Basis of Presentation
The accompanying financial statements are unaudited and have been prepared
by the Company pursuant to the rules and regulations of the Securities and
Exchange Commission ("SEC"). The December 31, 1997 balance sheet was derived
from audited financial statements, however, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to SEC rules and regulations. The Company believes that the financial
statements include all adjustments of a normal and recurring nature necessary to
present fairly the results of operations, financial position, changes in
stockholders' equity and cash flows for the periods presented. Results of
operations for interim periods are not necessarily indicative of those to be
achieved for full fiscal years. These financial statements should be read in
conjunction with the financial statements and notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 1997. There
have been no material changes in accounting policies from those stated in the
Company's Annual Report on Form 10-K for the year ended December 31, 1997.
3. Note Payable
The Company has entered into a credit arrangement with a commercial bank.
Borrowings under this credit arrangement bear interest at rates ranging from the
prime rate minus one quarter percent to 8.5%. As of June 30, 1998, the Company
had borrowed $2,500,000 under this credit arrangement, including $1,000,000
borrowed during the six months ended June 30, 1998. Any amounts outstanding
under this credit arrangement shall become immediately due and payable under
certain circumstances, including the failure by the Company to maintain certain
minimum cash and investment balances, as well as certain financial ratios. Under
the terms of the credit arrangement, the Company makes monthly interest-only
payments with all principal due in May 1999.
Although the entire outstanding principal balance is due within one year
from the balance sheet date, the Company has classified the entire $2,500,000
balance as long-term debt under the provisions of Statement of Financial
Accounting Standards No. 6, "Classification of Short Term Obligations Expected
to be Refinanced" ("SFAS 6"). In this regard, the Company has negotiated an
agreement with its commercial bank which permits the Company to refinance the
entire outstanding loan balance on a long-term basis. The terms of the
refinancing agreement are substantially the same as those in the Company's
existing credit arrangement, except that repayment is required on a date which
will be not less than one year and one day from May 1, 1999. The Company intends
to execute this agreement on or before May 31, 1999.
6
<PAGE>
4. Stockholders' Equity
The changes in stockholders' equity from December 31, 1997 to June 30, 1998 are
summarized as follows:
<TABLE>
<CAPTION>
Common Stock
Additional Other
Number Paid-in Accumulated Comprehensive
of Shares Amount Capital Deficit Income
--------- ------- ---------- ----------- -------------
<S> <C> <C> <C> <C> <C>
Balance at December 31, 1997 21,980 $ 44 $144,444 $(109,624) $ 6
Fair value of shares issued
under manufacturing 125 -- 859 -- --
agreement
Exercise of employee
stock options and warrants 173 1 127 -- --
Unrealized gain on
short-term investments -- -- -- -- 26
Loss -- -- -- (12,923) --
------ ---- -------- ---------- ----
Balance at June 30, 1998 22,278 $ 45 $145,430 $(122,547) $ 32
====== ==== ======== ========== ====
</TABLE>
Effective January 1, 1998 the Company adopted Statement of Financial
Accounting Standards No. 130, "Reporting Comprehensive Income" ("SFAS 130").
SFAS 130 establishes standards for the reporting of comprehensive income and its
components. Comprehensive income consists of reported net income or loss and
"other comprehensive income" (i.e. other gains and losses affecting
stockholders' equity that, under generally accepted accounting principals, are
excluded from net income or loss as reported on the statement of operations).
With regard to the Company, other comprehensive income consists of unrealized
gains and losses on marketable securities. The adoption of SFAS 130 affects only
the presentation of the Company's balance sheet, and does not affect the
Company's reported results of operations or cash flows.
The components of the Company's total comprehensive loss for the periods
noted are summarized as follows:
<TABLE>
<CAPTION>
Three Months Six Months
Ended Ended
June 30, June 30,
----------------------- ------------------------
1998 1997 1998 1997
-------- --------- ----------- ---------
<S> <C> <C> <C> <C>
Loss $ (6,273) $ (1,170) $ (12,923) $ (1,285)
--------- --------- ---------- ---------
Other comprehensive income:
Unrealized gain on securities held for sale 20 29 26 1
--------- --------- ---------- ---------
Total comprehensive loss $ (6,253) $ (1,141) $ (12,897) $ (1,284)
========= ========= ========== =========
</TABLE>
7
<PAGE>
5. Manufacturing Agreement
The Company is working with Abbott Laboratories ("Abbott") with regard to
the manufacture by Abbott of bulk drug substance for pexiganan acetate. The
Company's prior development arrangement with Abbott provides for the issuance by
the Company to Abbott of up to 500,000 shares of the Company's common stock and
the obligation to pay a royalty on any future sales of pexiganan acetate. Stock
issuances by the Company to Abbott will result in a charge to earnings,
representing the fair value of the shares when issued. As of June 30, 1998, the
Company has issued 250,000 shares of common stock to Abbott, including 125,000
shares issued during the six months ended June 30, 1998. The issuance of such
shares resulted in the recording of an earnings charge of $859,000 in the six
months ended June 30, 1998. Future stock issuances are related to the
achievement by Abbott of contractual performance milestones.
The Company expects to finalize an agreement with Abbott initially
providing for the purchase of approximately $10.0 million of bulk drug substance
for pexiganan acetate. As FDA approval of pexiganan acetate has not occurred,
this will result in charges to research and development expense in 1998 and
1999. However, there can be no assurance that such agreement will be
successfully negotiated. The Company is currently dependent upon Abbott for the
production of bulk drug substance for pexiganan acetate. In the event that bulk
drug substance for pexiganan acetate is not manufactured at Abbott, the Company
will need to secure other manufacturing arrangements. This would require
substantial funds and would also result in delays in the introduction of
pexiganan acetate to the market. The process developed by Abbott is proprietary,
and in the event the Company desires to utilize, or have another party utilize,
such proprietary technology the Company would be required to make license
payments to Abbott.
Further progress in scale-up and manufacturing development efforts will be
required to enable the Company to manufacture and sell pexiganan acetate on a
profitable basis. This will require substantial additional funds. The Company
has certain efforts under way with respect to alternative manufacturing sources,
including recombinant manufacturing; however, these programs are at an early
stage and significant expenditures over a period of time will be required to
develop a commercially viable process. No assurance can be given that a
cost-effective manufacturing process can ultimately be developed, or that any
such process would be approved by the FDA, or that the Company, Abbott or
another entity will be able to manufacture pexiganan acetate on a commercially
viable basis.
6. Collaborative Agreement
In February 1997, the Company entered into a development, supply and
distribution agreement (the "SB Agreement") in North America with SmithKline
Beecham ("SB") for pexiganan acetate. To date, SB has paid the Company $10.0
million under the SB Agreement, all of which was received by the Company in the
six months ended June 30, 1997. SB may make additional payments to the Company
of up to $22.5 million upon the occurrence of certain product milestones. SB
will also fund a percentage of any development expenses for any additional
indications for pexiganan acetate. Upon the commencement of commercial sales by
SB, the Company will be responsible for the supply of pexiganan acetate and SB
will be responsible for the marketing and sale of pexiganan acetate. The Company
will receive certain percentages of SB sales revenues under agreed upon terms.
The SB Agreement also gives SB the right to negotiate for rights to another of
the Company's product development candidate under certain terms and conditions.
The SB Agreement gives SB the right to terminate on a country-by-country basis
if SB determines it is not economical to distribute pexiganan acetate in such
areas.
8
<PAGE>
7. Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consist of the following (in thousands):
<TABLE>
<CAPTION>
June 30, December 31,
1998 1997
---- ----
<S> <C> <C>
Accounts payable $ 56 $ 215
Clinical and regulatory 857 1,197
Manufacturing costs 4,085 3,507
Preclinical costs 827 338
Professional fees 198 258
Other 943 429
------ ------
$6,966 $5,944
====== ======
</TABLE>
9
<PAGE>
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
This report contains, in addition to historical information, statements by
the Company with regard to its expectations as to financial results and other
aspects of its business that involve risks and uncertainties and may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements reflect management's current
views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of factors,
including, but not limited to, the risks and uncertainties discussed in this
report, as well as those discussed under "Risk Factors" set forth in Item 1 of
the Company's Annual Report on Form 10-K for the year ended December 31, 1997 as
filed with the Securities and Exchange Commission. Given these uncertainties,
current or prospective investors are cautioned not to place undue reliance on
any such forward-looking statements. Furthermore, the Company disclaims any
obligation or intent to update any such factors or forward-looking statements to
reflect future events or developments.
GENERAL
Magainin Pharmaceuticals Inc. (the "Company") is a biopharmaceutical
company engaged in the development of medicines for serious diseases. The
Company's development efforts are focused on anti-infectives, oncology, and
pulmonary and allergic disorders.
The Company has submitted a New Drug Application ("NDA") with the United
States Food and Drug Administration ("FDA") for its lead product development
candidate, pexiganan acetate (formerly called "Cytolex"), a topical cream
antibiotic intended for the treatment of infection in diabetic foot ulcers. The
Company is also conducting research on an aminosterol class of compounds. One
such compound, squalamine, is currently being evaluated in Phase I clinical
testing in cancer. The Company conducts additional research efforts in the
genomics of asthma.
Since commencing operations in 1988, the Company has not generated any
revenue from product sales. The Company has funded operations primarily from the
proceeds of public and private placements of securities. The Company has
incurred a loss in each year since its inception, and expects to incur
substantial additional losses for at least the next several years. The Company
expects that losses will fluctuate from quarter to quarter, and that such
fluctuations may be substantial. As such, results of operations for interim
periods are not necessarily indicative of those to be achieved for full fiscal
years. At June 30, 1998, the Company's accumulated deficit was approximately
$122,547,000.
RESULTS OF OPERATIONS
Revenues
The Company has received no revenue from product sales. Revenues recorded
to date have consisted principally of revenues recognized under collaborations
with corporate partners. During the three and six month periods ending June 30,
1997 the Company recorded revenue of $5,000,000 and $10,000,000, respectively,
reflecting the receipt of payment under a development, supply and distribution
agreement (the "SB Agreement") entered into in February, 1997 with SmithKline
Beecham ("SB") for pexiganan acetate. The Company does not expect to realize
additional milestone revenues from its arrangement with SB until FDA approval of
pexiganan acetate. However, there can be no assurance that pexiganan acetate
will be approved by the FDA. The Company has no other currently existing
collaborations which could result in the realization of research and development
revenues.
10
<PAGE>
Research and Development Expenses
Research and development expenses decreased slightly for the three month
period ended June 30, 1998 as compared to the same period a year ago. The
decrease in research and development expenses resulted from lower manufacturing
development costs associated with pexiganan acetate and squalamine, offset by
increases in clinical costs associated with the initiation of clinical testing
of squalamine and increased personnel costs.
Research and development expenses increased for the six month period ended
June 30, 1998 as compared to the same period a year ago. The increase is due
principally to the recording of a non-cash charge to earnings of approximately
$859,000 related to the issuance of 125,000 shares of common stock by the
Company pursuant to its manufacturing development arrangement with Abbott
Laboratories ("Abbott"). Additionally, research and development expenses
increased due to the initiation of clinical testing of squalamine and increased
personnel costs. These increases were partially offset by lower manufacturing
development costs associated with squalamine.
The level of research and development expenses in future periods will
depend principally upon the progress of research programs at the Company.
Expenses relating to the development of pexiganan acetate and squalamine are
expected to continue to be significant in future periods principally as a result
of the Company's ongoing manufacturing programs.
General and Administrative Expenses
General and administrative expenses consist principally of personnel costs
and professional fees and have increased for both the three and six month
periods ended June 30, 1998, as compared to the same periods a year ago, due to
increases in professional fees and personnel expenses. The Company expects
general and administrative expenses to increase in future periods as the
Company's level of activity increases.
Interest Income and Interest Expense
During the three months ended June 30, 1998, interest income remained
essentially the same as compared to the same period of the prior year, due to
consistent investment balances during this period. Interest income increased for
the six month period ended June 30, 1998 as compared to the same period a year
ago principally due to higher investment balances in 1998. The increase in
interest expense for both the three and six month periods ended June 30, 1998,
as compared to the same periods in the prior year, is due to higher debt
balances.
Loss
The Company expects to conduct, over the next several years, significant
research, pre-clinical development, clinical testing and manufacturing
activities which, together with projected general and administrative expenses,
are expected to result in continued and significant losses, particularly due to
the extended time period before the Company expects to commercialize any
products.
11
<PAGE>
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
Cash and investments were $28,846,000 at June 30, 1998 as compared to
$39,061,000 at December 31, 1997. The primary use of cash was to finance the
Company's operations.
Since inception, the Company has funded its operations primarily from the
proceeds of public and private placements of securities, including $17,080,000
raised from its initial public offering in December 1991, $21,469,000 raised
from a public offering completed in February 1993, $18,023,000 raised from a
private placement completed in October 1993, $32,627,000 raised from a public
offering completed in August 1995, $11,932,000 raised from a private placement
completed in August 1996, and $19,172,000 raised from a public offering
completed in December 1997, as well as contract and grant revenues, interest
income and lease and debt financing.
Capital expenditures amounted to $913,000 in the six months ended June 30,
1998, principally reflecting the build-out of additional laboratory space,
office and laboratory equipment purchases and construction of leasehold
improvements.
Accounts payable and accrued expenses increased $1,022,000 to $6,966,000 at
June 30, 1998, due principally to accruals made for certain manufacturing,
clinical and preclinical costs. The Company expects an increase in accounts
payable and accrued expenses in future periods as costs for the purchase of bulk
drug substance for pexiganan acetate are accrued.
During the first half of 1998 the Company borrowed an additional $1,000,000
under a credit arrangement with a commercial bank, resulting in an increase in
note payable. Borrowings under this credit arrangement bear interest at rates
ranging from the prime rate minus one quarter percent to 8.5%. Any amounts
outstanding under this credit arrangement shall become immediately due and
payable under certain circumstances, including the failure by the Company to
maintain certain minimum cash and investment balances, as well as certain
financial ratios. Under the terms of the credit arrangement, the Company makes
monthly interest-only payments, with all principal due in May 1999. Although the
entire outstanding principal balance is due within one year from the balance
sheet date, the Company has classified the entire $2,500,000 balance as long-
term debt under the provisions of Statement of Financial Accounting Standards
No. 6, "Classification of Short Term Obligations Expected to be Refinanced"
("SFAS 6"). In this regard, the Company has negotiated an agreement with its
commercial bank which permits the Company to refinance the entire outstanding
loan balance on a long-term basis. The terms of the refinancing agreement are
substantially the same as those in the Company's existing credit arrangement,
except that repayment is required on a date which will be not less than one year
and one day from May 1, 1999. The Company intends to execute this agreement on
or before May 31, 1999.
In February 1997, the Company entered into a development, supply and
distribution agreement (the "SB Agreement") in North America with SmithKline
Beecham ("SB") for pexiganan acetate. Through June 30, 1998, SB has paid the
Company $10,000,000 under the SB Agreement, all of which was received by the
Company during the six months ended June 30 1997. SB may make additional
payments to the Company of up to $22,500,000 upon the occurrence of certain
product milestones. SB will also fund a percentage of any development expenses
for any additional indications for pexiganan acetate. Upon the commencement of
commercial sales by SB, the Company will be responsible for the supply of
pexiganan acetate and SB will be responsible for the marketing and sales of
pexiganan acetate. The Company will receive certain percentages of SB sales
revenues under agreed upon terms. The SB Agreement also gives SB the right to
negotiate for rights to another of the Company's product development candidate,
under certain terms and conditions. The SB Agreement gives SB the right to
terminate on a country-by-country basis if SB determines it is not economical to
distribute pexiganan acetate in such areas.
12
<PAGE>
The Company has submitted a New Drug Application ("NDA") with the FDA for
pexiganan acetate. The NDA submission includes the results of two multi-center,
randomized, Phase III clinical equivalence trials comparing 1% pexiganan acetate
cream to ofloxacin, an oral antibiotic indicated for skin and soft tissue
infections. The NDA, as submitted, includes data analyses for a number of
primary endpoints. These include clinical response of infection, overall
microbiological response of infection, and therapeutic cure (a combination of
clinical and overall microbiological cures), which were analyzed over a number
of patient cohorts and timepoints. The Company's analyses of the data showed
statistical equivalence between pexiganan acetate and ofloxacin in the majority
of such endpoints. Although the Company believes the two pivotal trials of
pexiganan acetate yielded successful results, there can be no assurance that the
FDA will concur with the Company's analysis in this regard. There can be no
assurance that pexiganan acetate will receive FDA approval on a timely basis, if
at all. The failure of the Company to obtain FDA approval for pexiganan acetate,
any significant delay in obtaining such approval, or the imposition of highly
restrictive conditions on such approval, would have a material adverse effect on
the Company.
The Company believes that its existing capital resources should be
sufficient to finance its operations into 1999. However, the Company's capital
requirements may change due to numerous factors, including the progress of the
Company's research and development programs, regulatory approvals, competitive
and technological advances, the commercial viability of the Company's products,
the terms of collaborative arrangements, if any, entered into by the Company,
and other factors, many of which are beyond the Company's control. The Company
will require substantial additional funds to continue its research and
development programs and to commercialize potential products. The Company
intends to seek such funds through a combination of future offerings of
securities and collaborative arrangements with third parties, and regularly
explores alternatives in this regard. The Company does not have any commitments
to obtain any additional funds and has no established banking arrangements
through which it can obtain additional debt financing. There can be no assurance
that future funding will be available to the Company, or if available, will be
obtainable on terms favorable to the Company. The receipt of funding, if any,
from corporate partners, including SB, will depend largely on the progress of
research and development programs. Under collaborative arrangements the Company
may convey marketing, distribution, manufacturing, development or other rights
to its proposed products to pharmaceutical companies in order to receive
financial or other assistance. This will result in lower consideration to the
Company upon commercialization of such products than if no arrangements were
entered into, or if such arrangements were entered into at later stages in the
product development process. There can be no assurance that the Company will be
able to enter into such arrangements on favorable terms, if at all.
If the Company does not enter into appropriate collaborations, receive
additional funds from SB under its current agreement, or raise sufficient funds
from the periodic sale of securities, the Company will be required to delay or
eliminate expenditures for potential products, including pexiganan acetate, or
to enter into collaborations with third parties to commercialize potential
products or technologies that the Company would otherwise seek to develop
itself, or seek other arrangements.
13
<PAGE>
The Company expects to finalize an agreement with Abbott initially
providing for the purchase of approximately $10.0 million of bulk drug substance
for pexiganan acetate. As FDA approval of pexiganan acetate has not occurred,
this will result in charges to research and development expense in 1998 and
1999. However, there can be no assurance that such agreement will be
successfully negotiated. The Company is currently dependent upon Abbott for the
production of bulk drug substance for pexiganan acetate. In the event that bulk
drug substance for pexiganan acetate is not manufactured at Abbott, the Company
will need to secure other manufacturing arrangements. This would require
substantial funds and would also result in delays in the introduction of
pexiganan acetate to the market. The process developed by Abbott is proprietary,
and in the event the Company desires to utilize, or have another party utilize,
such proprietary technology the Company would be required to make license
payments to Abbott.
Further progress in scale-up and manufacturing development efforts will be
required to enable the Company to manufacture and sell pexiganan acetate on a
profitable basis. This will require substantial additional funds. The Company
has certain efforts under way with respect to alternative manufacturing sources,
including recombinant manufacturing; however, these programs are at an early
stage and significant expenditures over a period of time will be required to
develop a commercially viable process. No assurance can be given that a
cost-effective manufacturing process can ultimately be developed, or that any
such process would be approved by the FDA, or that the Company, Abbott or
another entity will be able to manufacture pexiganan acetate on a commercially
viable basis.
The Company's prior development arrangement with Abbott provides for the
issuance by the Company to Abbott of up to 500,000 shares of its Common Stock
and the obligation to pay a royalty on any future sales of pexiganan acetate.
Stock issuances by the Company to Abbott will result in a charge to earnings,
representing the fair value of the shares when issued. As of June 30, 1998, the
Company has issued 250,000 shares of common stock to Abbott, including 125,000
shares issued during the six months ended June 30, 1998. The issuance of such
shares resulted in the recording of an earnings charge of $859,000 in the six
months ended June 30, 1998. Future stock issuances are related to the
achievement by Abbott of contractual performance milestones.
The Company also expects to conduct significant manufacturing development
activities for its other products under development. The Company is currently
working with outside contractors for the chemical production of squalamine. The
Company expects to expend significant resources in the chemical synthesis of
squalamine and other compounds under development, however, there can be no
assurance that these efforts will be successful.
The Company's capital expenditure requirements will depend upon numerous
factors, including the success of pexiganan acetate and the progress of the
Company's other research and development programs, the time and cost required to
obtain regulatory approvals, the ability of the Company to enter into additional
collaborative arrangements, the demand for products based on the Company's
technology, if and when such products are approved, and possible acquisitions of
products, technologies and companies. The Company had no significant capital
commitments as of June 30, 1998.
The Company is working to resolve the potential impact of the year 2000 on
the ability of the Company's computerized information systems to accurately
process information that may be date-sensitive. Any of the Company's programs
that recognize a date using "00" as the year 1900 rather than the year 2000
could result in errors or system failures. The Company utilizes a number of
computer programs across its entire operation. The Company has not completed its
assessment, but currently believes that costs of addressing this issue will not
have a material adverse impact on the Company's financial position. However, if
the Company and third parties upon which it relies are unable to address this
issue in a timely manner, it could result in a material financial risk to the
Company. In order to assure that this does not occur, the Company plans to
devote all resources required to resolve any significant year 2000 issues in a
timely manner.
14
<PAGE>
PART II - OTHER INFORMATION
ITEM 1. Legal Proceedings
None
ITEM 2. Changes in Securities
None
ITEM 3. Defaults Upon Senior Securities
None
ITEM 4. Submission of Matters to a Vote of Security Holders
At the Company's Annual Meeting of Stockholders' held on May 13, 1998 the
stockholder's elected nine directors and approved the adoption of the Magainin
Pharmaceuticals Inc. 1998 Equity Compensation Plan.
A) In the election of the directors the number of shares voted was as
follows:
<TABLE>
<S> <C> <C>
For Withheld
--- --------
Jay Moorin 19,432,106 514,817
Michael A. Zasloff, M.D., Ph.D. 19,819,838 127,085
Bernard Canavan, M.D. 19,839,898 107,025
Michael R. Dougherty 19,840,053 106,870
Zola P. Horovitz, Ph.D. 19,837,698 109,225
Roy C. Levitt, M.D. 19,841,963 104,960
Charles A. Sanders, M.D. 19,838,498 108,425
Robert F. Shapiro 19,839,368 107,555
James B. Wyngaarden, M.D. 19,835,938 110,985
</TABLE>
B) In the adoption of the Magainin Pharmaceuticals Inc. 1998 Equity
Compensation Plan the number of shares voted was as follows:
<TABLE>
<S> <C> <C> <C>
For Against Withheld
--- ------- --------
10,543,160 5,165,808 52,746
</TABLE>
ITEM 5. Other Information
None
ITEM 6. Exhibits and Reports on Form 8-K
27 Financial Data Schedule
15
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Magainin Pharmaceuticals Inc.
(Registrant)
Date: August 13, 1998 /S/ Michael R. Dougherty
------------------------
Michael R. Dougherty
President, Chief Executive Officer
and Chief Financial Officer
16
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE NAMED
REGISTRANT FINANCIAL STATEMENTS INCLUDED IN ITS REPORT ON FORM 10-Q FOR THE
QUARTERLY PERIOD ENDED JUNE 30, 1998,
</LEGEND>
<MULTIPLIER> 1,000
<S> <C> <C>
<PERIOD-TYPE> 6-MOS 6-MOS
<FISCAL-YEAR-END> DEC-31-1998 DEC-31-1997
<PERIOD-START> JAN-01-1998 JAN-01-1997
<PERIOD-END> JUN-30-1998 JUN-30-1997
<CASH> 1,142 487
<SECURITIES> 27,704 38,574
<RECEIVABLES> 0 0
<ALLOWANCES> 0 0
<INVENTORY> 0 0
<CURRENT-ASSETS> 29,265 39,551
<PP&E> 6,800 5,772
<DEPRECIATION> 3,661 2,948
<TOTAL-ASSETS> 32,503 42,444
<CURRENT-LIABILITIES> 6,966 6,478
<BONDS> 0 0
0 0
0 0
<COMMON> 45 44
<OTHER-SE> 22,915 34,826
<TOTAL-LIABILITY-AND-EQUITY> 32,503 42,444
<SALES> 0 0
<TOTAL-REVENUES> 0 10,075
<CGS> 0 0
<TOTAL-COSTS> 0 0
<OTHER-EXPENSES> 13,783 12,186
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 84 44
<INCOME-PRETAX> (12,923) (1,285)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> (12,923) (1,285)
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (12,923) (1,285)
<EPS-PRIMARY> (0.58) (0.07)
<EPS-DILUTED> (0.58) (0.07)
</TABLE>
